{
    "nct_id": "NCT05444894",
    "official_title": "A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)",
    "inclusion_criteria": "Diagnosis of Transfusion Dependent B-Thalassemia as defined by:\n\n* Documented homozygous β-thalassemia or compound heterozygous β-thalassemia including β-thalassemia/hemoglobin E (HbE) based on historical data in medical records, and\n* History of at least 100 mL/kg/year or 10 U/year of packed red blood cell (RBC) transfusions in the 2 years prior to signing informed consent\n* Clinically stable and eligible to undergo autologous HSCT\n* Karnofsky Performance Status ≥ 70\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 35 Years",
    "exclusion_criteria": "* Available 10/10 human leukocyte antigen (HLA)-matched related donor\n* Prior HSCT or contraindications to autologous HSCT\n* Participants with associated a history of α-thalassemia and > 1 alpha chain deletion, or alpha multiplications as documented in medical records\n* Participants with a history of other inherited hemoglobinopathy or thalassemic mutation (Hb S, C, D or other) as documented in medical records\n* Prior receipt of gene therapy\n* Inadequate bone marrow function, as defined by white blood cell count of < 3 x 10^9/L or a platelet count < 100 x 10^9/L (without hypersplenism), per investigator judgement\n* Inadequate organ function\n* Advanced liver disease\n* Any prior or current malignancy, or immunodeficiency disorder,\n* Immediate family member with a known or suspected Familial Cancer Syndrome\n* Clinically significant and active bacterial, viral, fungal, or parasitic infection",
    "miscellaneous_criteria": "Key"
}